Currently, ICIs primarily target PD-1/PD-L1, which are immune-checkpoint molecules that inhibit the priming phase (activation of antigen-presenting cells and T cells) and effector phase (direct damage to cancer cells) of the cancer-immunity cycle (7). The gene discussed is PDCD1; the disease is cancer.